Dewpoint Therapeutics raise $77m in Series B financing
A $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies.
Kurma Partners close diagnostics fund at 50m
The only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at 50m.
Danish Galecto Inc. secures US$64m equity financing
Danish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital.
MosaMeat NV bags US$55m financing
Maastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m.
Pureos Bioventures closes US$170m fund
Newly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers.
Biotechs request money for COVID therapeutics
German biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
Polyneuron Pharmaceuticals AG extends Series A financing
Swiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.
Mabion to licence COVID-19 jab from Vaxine Pty Ltd
Polish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19
MiNA Therapeutic bags £23m financing
RNA therapeutics specialist MiNA Therapeutics plc has secured £23m in a Series A financing to push development its first-in-class small activating RNA (saRNA) candidates.
Vaccine developers unite to stand with science
Nine CEOs of COVID-19 vaccines have assured that safety of vaccinated individuals remains their top priority in development of the first COVID-19 vaccines.